If you’re looking at treatment options for type 2 diabetes, you may want to learn more about Trulicity (dulaglutide). It’s a prescription drug used in adults to help with the following: Trulicity ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...

(Reuters) - Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with ...

SAN FRANCISCO -- The GLP-1 receptor agonist dulaglutide (Trulicity) slowed renal function decline in some patients with type 2 diabetes and poor kidney functioning, researchers said here, and they ...

Eli Lilly has re-entered the GLP-1 class of diabetes treatment following the US approval of Trulicity. The FDA gave the green light to the drug to improve glycaemic control in adults with type 2 ...

Medicare Part D and some Medicare Advantage (Part C) plans may cover Trulicity for managing type 2 diabetes, but coverage specifics depend on the plan’s formulary (drug list). Medicare typically does ...

(Reuters) - Eli Lilly and Co <LLY.N> third-quarter sales missed Wall Street estimates on Wednesday as rebates limited revenue from its top-selling diabetes drug Trulicity, and its shares fell about 4% ...

Trulicity (dulaglutide) is a prescription drug used to treat type 2 diabetes and lower certain cardiovascular risks. This drug can interact with other medications and some supplements. For example, ...

Dec 16 (Reuters) - The U.S. health regulator has added Eli Lilly and Co's (LLY.N), opens new tab Mounjaro to its list of drugs facing shortages, highlighting the company's struggles to meet booming ...